

ZEA Biosciences to Begin Eugenol Hypertension Clinical Trial with Native American Population

ZEA will evaluate Tulsi Basil as a natural treatment for hypertension

WALPOLE, MASSACHUSETTS, UNITED STATES, July 9, 2020 /EINPresswire.com/ -- ZEA Biosciences will begin evaluating potential individuals for entry into a [clinical trial](#) in order to measure and

offer treatment for hypertension within the Native American population.



Our hope is to help Native Americans who have been disproportionately affected by hypertension. Ultimately, we would like to offer Native Americans a natural alternative to help treat this disease."

James Wilson, Founder and CEO of ZEA Biosciences

Approximately 27% Native Americans have been diagnosed with hypertension. ZEA will monitor the effectiveness of Tulsi Basil as a natural treatment for hypertension. Research has shown that Tulsi Basil and its active ingredient, Eugenol, can help treat hypertension.

In this trial, participants who have been diagnosed with hypertension will drink Tulsi Basil tea. Over the course of 90 days, their blood pressure will be recorded and monitored.

The National Institutes of Health states that plant biologics like Tulsi Basil are safer, scalable, and much less expensive than their synthetic counterparts. In fact, the NIH also states that plant biologics may help control potential pandemics in the future, because of how quickly they can be made.

"Our hope is to help Native Americans who have been disproportionately affected by hypertension. The clinical trials will show whether drinking Tulsi Basil tea will lower the blood pressure of this population," said James Wilson, Founder and CEO of ZEA Biosciences.

"Ultimately, we would like to offer the Native Americans a natural alternative to help treat this terrible disease," he added.

LYNDA BASSETT
ZEA BIOSCIENCES
+1 857-334-1644

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/521308691>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.